Nascent Biotech Inc. (NBIO)

[subslover]

Item 1.01 Material Definitive Contract.



On April 30, 2020, Nascent Biotech Inc. (the “Company”) entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (“MBI”), an unrelated third party, to initiate a vaccine program for the potential prevention of COVID-19 or other viral infections.



Under the terms of the agreement the Company will fund the project through equity of $200,000 and receive an exclusive royalty-based license on any intellectual property discovered for the usage with the prevention of coronaviruses.